PYC Therapeutics (PYC) H2 2024 earnings summary

Executive summary

• Advanced to clinical stage with three drug programs targeting rare genetic diseases in eye and kidney, with human trials ongoing or imminent for Retinitis Pigmentosa type 11 (RP11), Autosomal Dominant Optic Atrophy (ADOA), and Polycystic Kidney Disease (PKD).

• Lead candidate VP-001 for RP11 showed safety and early efficacy in Phase 1, progressing to multiple dose studies; ADOA program received Orphan Drug and Rare Pediatric Disease Designations from FDA.

• Expanded pipeline with preclinical progress in Phelan-McDermid Syndrome and AI-driven drug discovery collaboration with Google Cloud.

• Raised $75 million in capital to fund clinical programs and maintain strong cash reserves.

Financial highlights

• Total income for FY2024 was $22.9 million, up $7.0 million year-over-year, driven by higher R&D tax incentive, interest income, and $4.5 million from AI collaboration.

• Operating loss after tax increased to $38.1 million (FY2023: $23.4 million), reflecting higher R&D expenditure of $56.4 million (up $21.3 million year-over-year).

• Cash and cash equivalents at 30 June 2024 were $66.9 million (2023: $15.6 million), with total available funding expected to reach $84 million after R&D tax rebate.

• Net assets at year-end were $81.1 million (2023: $28.4 million).

Outlook and guidance

• Multiple safety and efficacy readouts expected across all three clinical programs within the next 18 months.

• Human trials for PKD anticipated to commence in early 2025, with potential for first commercial revenue as early as 2028.

• Future funding needs expected to be modest relative to potential asset value; options include asset licensing or further equity issuance.